NewsUp one level
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology.
EFPIA and the Innovative Medicines Initiative announced the launch of a €280 million Call for proposals for an Innovative Medicines Initiative (IMI) programme aimed to address the current Ebola crisis.
Preliminary information on the topics scheduled for launch under the second Call for proposals under IMI 2 is available
A major step in implementing the ETPN Translation Hub has been reached, with three European projects entering the finalisation stage of their EU Grant Agreements. The project ENATRANS is for networking of SMEs in the nano-biomedical sector and supporting the SMEs with getting their products from the laboratory phase to the clinical applications. The projects 'NANOFACTURING' and 'NANOPILOT' will establish pilot lines to scale-up the production of novel nanopharmaceuticals from the lab-scale to the quantities needed for clinical testing. This announcement took place during the ETPN Annual Event 2014 in San Sebastian, Spain.
2nd European workshop on novel aspects of Nanomedicine entitled "Nanomedicine Now - The Challenge to Translate Scientific Results to Applications for patients" will be held on Thursday, November 27th, 2014 at the Council of Europe in Strasbourg.
A brokerage event for the incoming H2020 NMBP work program is organized by the European Technology Platform NANOfutures with the collaboration of EUMAT and Manufuture and ETPN.
ETPN Annual Event 2014 Press Release: Setting up the next Nanomedicine priorities and services for the field until 2020
The European Technology Platform on Nanomedicine (ETPN) organises its 2014 Annual Event & General Assembly in San Sebastian, Spain. The event will take place on October 15th and 16th, kindly co-organised by the nanoBasque Agency (SPRI) and hosted by CIC nanoGUNE, the Basque nanoscience cooperative research centre.
An article published, by Tore Skotland, Tore-Geir Iversen and Kirsten Sandvig from the Centre for Cancer Biomedicine and the Institute for Cancer Research of the Oslo University Hospital and members of the European Technology Platform on Nanomedicine (ETPN) has been recently released.
Results from 2B3-201 Dose-ascending Trial Presented at Joint ACTRIMS/ECTRIMS Meeting
The ETPN continues its collaboration and series of nanomedicine articles with the International Innovation magazine, with an overview of nanomedicine based solutions to improve the diagnostics and therapy of Alzheimer's disease.
The Education in Nano Technologies (EduNano) projects is currently assessing industry employment needs and the needs of academic researchers through a survey with the goal to develop online courses.
SPIE Microtechnologies, the European meeting where the latest technologies and applications in nanotechnology, microtechnology, as well as bioMEMs, and medical microdevices, smart sensors and integrated circuits and systems are presented.
New position published in the Jobs' section: Marie Curie - Post-Doctoral Researcher in Drug Development
Procarta Biosystems Ltd, Norwich, UK, in collaboration with the Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase, Florence, Italy, University of East Anglia, Norwich, UK, and Nanovector, Turin, Italy, are looking to recruit an experienced researcher.
The ETPN released its Newsletter 3/2014, compiling internal news but also nanomedicine news, upcoming events, information on future calls, ...
The Opening Session of the European Summit for Clinical Nanomedicine 2014 is now available on YouTube.
Registration for the IMI 2 Info Day on 30 September in Brussels, Belgium is now open, until 23 September, via the event web page.
Dr Laurent Lévy speaks to Hannah Stanwix, Commissioning Editor. L Lévy is the Co-Founder, CEO, President of the Executive Board and a shareholder of Nanobiotix, a clinical-stage nanomedicine company pioneering NanoXray, a novel approach for the local treatment of cancer. L Lévy is the Vice-Chairman of the European Technology Platform on Nanomedicine (ETPN)
euMatch is the new matchmaking tool supporting partnering and partner search for your efficient participation in EU Horizon 2020 programme
As the SME Instrument is a brand new funding opportunity, it was not known what to expect from the first round of applications. As it is said on many occasions, the Instrument is very selective and only the best of the best can succeed.
Nanomedicine is an emerging space with many companies spending on research to explore this field in greater depth. Nanoparticles, which are of one to 100 nm, because of their characteristic of being very small are perfect for reaching cellular levels. Research in this field can open new avenues of treating diseases which were initially considered untreatable.
The parts of the Work Programmes 2014–2015 that relate to 2015 (topics, dates, budget) have, with these revised versions, been updated.
The ETP Nanomedicine is currently expanding its range of collaborations with non-European countries in order to create new opportunities for its members. Besides USA, first contacts have been established with Argentina.
The Fit4Health project organises a webinar on 9th September focussed on the description and implementation of clinical trials in Horizon 2020 proposals.
DG SANCO launched a Public Consultation on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices
The European Commission and the Scientific Committee on Emerging Newly Identified Health Risks have launched a public consultation on the Preliminary opinion ‘Guidance on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices’.
The projects launched in the 1st Joint Translational Call in 2009 for research groups operating in the EuroNanoMed II partner countries have been finished.